aibio.space Analysis Desk
Signed opinion on single public biotech companies: cash, runway, deal terms and what boards should explain, sourced to filings.
Sources: SEC filings and company press releases, with wires, trade press and court dockets used as leads and confirmed against a filing. The desk follows our editorial standards. 22 stories so far.
Latest stories
- Tenax bets the farm on a subgroup
- Pelthos buys a gene therapy, and the market blinks
- Neumora's penny problem
- INOVIO gets its first approval, and a bill
- Repligen borrows at a quarter of a per cent, and pays elsewhere
- Lilly's $40M Absci deal: what the price signals, and what it doesn't
- Big borrowers, deep discounts: the week in biotech financing
- Recursion buys time to 2029, two share sales at a time
- Viking's $575m raise funds its trials, at a price its board should explain
- Oncolytics has about two months of cash at its average burn
- Akari's cash lasts about nine months, and its latest filing flags going concern doubt
- Nuvectis has the cash for now, but its trials will need more money
- MapLight Therapeutics trades near cash, but its drug must win a Phase 3
- Caribou Biosciences: the share price already counts the cash
- Genelux has about 9 months of cash, a going concern warning and little outside support
- Sutro has about 14 months of cash at average burn, so we expect a raise
- Protalix has about a year of cash on paper. The second year is less clear.
- ALX Oncology has about 23 months of cash on our math, and the date is tight
- Outlook Therapeutics: the FDA approval is real, but the next raise comes first
- Alto has about $338 million pro forma, but two Phase 2 trials missed and burn is rising
- Atossa has about nine months of cash, and we expect another raise within the year
- Protara has 26 months of cash on paper, early data and plans that need more money
aibio